Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25109489 | 0.96 | RORC (0.44) | RORCHRH3CHKAHDAC3HDAC8 | |
| SCHEMBL25481265 | 0.88 | RORC (0.42) | RORCHRH3CHKAHDAC3HDAC8 | |
| SCHEMBL25481459 | 0.87 | HRH3 (0.43) | RORCHRH3ALDH1A1KDM4EMAPT | |
| SCHEMBL25110451 | 0.87 | CHKA (0.47) | RORCHRH3CHKAHDAC3HDAC8 | |
| SCHEMBL25481244 | 0.82 | HRH3 (0.40) | RORCHRH3CHKANCF1KMT2A | |
| SCHEMBL25110842 | 0.81 | HRH3 (0.40) | RORCHRH3HDAC3HDAC8KDM4E | |
| SCHEMBL22794340 | 0.81 | HRH3 (0.61) | RORCHRH3ALDH1A1KDM4EMAPT | |
| SCHEMBL25108392 | 0.80 | RORC (0.39) | RORCHRH3CHKANCF1ALDH1A1 | |
| SCHEMBL24513988 | 0.80 | HRH3 (0.57) | HRH3ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL22794555 | 0.79 | HRH3 (0.56) | HRH3ALDH1A1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | RORC 2353/4885HRH3 1490/4885CHKA 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.